Circulating Endothelial Progenitor Cells Are Up-Regulated in a Mouse Model of Endometriosis

Christian M Becker, Becker CM, Paul Beaudry, Beaudry P, Tae Funakoshi, Funakoshi T, Ofra Benny, Benny O, Alexander Zaslavsky, A. Zaslavsky, Zaslavsky A, Zurakowski D, David Zurakowski, Folkman J, Judah Folkman, D'Amato RJ, Robert J. D’Amato, Robert J D'Amato, Sandra Ryeom, Ryeom S
The American journal of pathology · 2011 · vol. 178(4) , pp. 1782–1791 · doi:10.1016/j.ajpath.2010.12.037 · PMID:21435458 · PMC3070089 · W2082371998
article OA: gold CC0 ⤵ 56 in-corpus citations
📄 Open PDF Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

In a mouse model of endometriosis, circulating endothelial progenitor cells were found to be up-regulated, suggesting a role in neovascularization.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-12 · read from full text ⓘ

This study used a surgically induced mouse model of endometriosis to measure circulating endothelial cells (CECs) and endothelial progenitor cells (EPCs) in peripheral blood by flow cytometry, comparing mice with endometriotic lesions, sham surgery, and nonoperated controls across different time points and mouse strains. Key findings were that EPC counts rose significantly at 1 week after endometriosis induction, with a clear increase over controls in the more angiogenic 129/SvJ strain, whereas CECs and the endometriosis-vs-sham differences were described as marginal or not significant depending on strain and lesion number. The authors report an additional angiogenesis-inhibition arm using TNP-470 (Lodamin) in a later set of experiments and performed bone marrow transplantation experiments in some cohorts to assess EPC origin, but the excerpted results focus on early EPC changes after surgery. This paper is centrally about endometriosis — it demonstrates up-regulation of circulating endothelial progenitor cells in a mouse model of endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Endometriosis is a debilitating disease characterized by the growth of ectopic endometrial tissue. It is widely accepted that angiogenesis plays an integral part in the establishment and growth of endometriotic lesions. Recent data from a variety of angiogenesis-dependent diseases suggest a critical role of bone marrow–derived endothelial progenitor cells (EPCs) in neovascularization. In this study the of and endothelial cells in a of of in the of that a the of endometriotic and of In a bone endothelial cells endometriotic by and of the angiogenesis an of data an role bone marrow–derived endothelial cells in the of and the of a this Endometriosis is a debilitating disease characterized by the growth of ectopic endometrial tissue. It is widely accepted that angiogenesis plays an integral part in the establishment and growth of endometriotic lesions. Recent data from a variety of angiogenesis-dependent diseases suggest a critical role of bone marrow–derived endothelial progenitor cells (EPCs) in neovascularization. In this study the of and endothelial cells in a of of in the of that a the of endometriotic and of In a bone endothelial cells endometriotic by and of the angiogenesis an of data an role bone marrow–derived endothelial cells in the of and the of a this of of disease debilitating and of and In is is of the of the endometriotic the and of a a and of of in of in and and of a of of the of of of endometriotic of the In the is the and is and of an the and In an of and a of Endometriosis and the the of the the of by and that the of a is the establishment and growth of endometriotic and in in of angiogenesis a of and in the growth of endometriotic of in a of of endothelial growth growth and growth of angiogenesis and in endometriotic a of of endothelial of in disease and of in and of endothelial cells endothelial cells from the bone of progenitor endothelial cells endothelial endothelial growth is in endometriotic and of endothelial growth in endothelial growth in of of endothelial growth in the angiogenesis the and in the of is a the of bone marrow–derived endothelial progenitor cells by bone endothelial progenitor in by of and and in by of endothelial growth in of the of of in and the of of the progenitor cells the in progenitor cells of and of endothelial and cells angiogenesis and endothelial and of and the of endothelial cells from of endothelial growth endothelial and endothelial a of that and disease and of in of the of and growth angiogenesis of in the of an of growth and in this study the role of of an of of and a bone the of the of endometriotic lesions. the of and and in the and in and and by the and of from from and from a from of cells of and bone in of and a of from of the of the by the growth of endometriotic the the in and Endometriosis the growth of endometriotic endothelial in and in a of in a the of in the the a and in a in of a and the the the endometrial the a a in the that of endometrial tissue. in the of the and the the of the of a the of a the growth of endometriotic and growth of in a of of the of the a In of the in a and of the an of the angiogenesis by and in and the of the the of In the bone bone endometriotic from progenitor cells In bone from and and bone bone the of the in bone by of and in the of of the of of by and of and of endothelial cells of endothelial growth endothelial and endothelial a of and the and of endothelial progenitor the endothelial growth of endothelial progenitor cells the the of cells in and endometriotic from that a bone and in the in and in and and in and the the a and data and and in endothelial angiogenesis by a and of endothelial growth endothelial and endothelial a of endothelial cells in and and bone marrow–derived progenitor endothelial cells of endothelial growth endothelial and endothelial a of and the and of endothelial progenitor the endothelial growth of endothelial progenitor endothelial in and and an in and in and and the and from in in and in that a and progenitor cells of and in of cells of and and the and data and data in of of the of of in a of the of in a of by in endometriotic lesions. of endothelial growth endothelial and endothelial a of by of endothelial and and the of and by and in a of and of of endothelial growth endothelial and endothelial a of progenitor cells In the of and a the the the and of the of of angiogenesis in of the of angiogenesis in a in the that a and the of the of endometriotic disease a in a in the and a from the in of and in the and of endothelial cells from endometriotic and endometriotic a the of an the growth of endometriotic endothelial in and in a and growth of in a of of the of in a and and and and and in that that a in the by the of bone cells in the in the endometriotic and in the and endometriotic and and endothelial cells by the of and and of a a in the of endothelial cells the endometriotic in cells in endometriotic lesions. bone from endometriotic from and from and and and of and endothelial cells of cells of cells of cells of and endothelial of endometriotic in bone and of and cells of bone marrow–derived cells in endometriotic in bone marrow–derived cells endothelial cells that and of cells in the endometriotic the the of a in the of endothelial cells in endometriotic and in of cells the of endometriotic by an an endothelial that the of endothelial progenitor cells endometriotic the of and endometriotic growth in and growth of in a of of the of is an of of the angiogenesis and of endometriotic by the the of of and of in the and of and of the of an of the angiogenesis the of the of and of and a the of an of of of of the in the the that the of endothelial cells and endothelial progenitor cells in the of an angiogenesis-dependent the of a in the the study that endothelial progenitor cells in an of and that cells the of the endometriotic lesions. growth of the of the angiogenesis in a of this of and of a role in the angiogenesis-dependent growth of endometriotic and the of a of disease and of is in that growth disease establishment and the angiogenesis in of endothelial and and of in disease and and of angiogenesis in In the the of bone marrow–derived endothelial progenitor cells the of and the in a that the of the the role of in the and of of endothelial and cells angiogenesis and endothelial in and In that of endothelial cells in the bone marrow–derived of bone marrow–derived cells in the this the of bone marrow–derived endothelial cells a of in the in the of endothelial progenitor and the endothelial progenitor cells and in this in in a that cells of endometriotic in a endothelial cells the the and the that the of the endothelial cells in the data suggest that bone marrow–derived endothelial cells this of is a disease that of in the growth and in endometriotic of of endothelial growth in the angiogenesis the and in the of of growth in from in of is a endothelial cells and of It that plays a role in the of bone progenitor cells by bone endothelial progenitor that is of the the of in this data that in the the and in and by a the by a the In a in of and in the and growth of in a of of in the of and of the of of endometriotic in a in in the that a is in growth and growth by cells from of and progenitor cells from the bone of endothelial progenitor in the of and of in ectopic and of and of and of growth in the of endothelial cells in that a and in this in the that of the and in the of cells from the in that this in the this the in a that of the endothelial cells from the a role a in and in and the by angiogenesis a the of angiogenesis in and of angiogenesis in is an of of the by the angiogenesis and in and that the angiogenesis and the and of endometriotic growth the growth of endometriotic endothelial in and in a a is a angiogenesis that endometriotic of that angiogenesis and the of in the that in and study of and of an angiogenesis in in is an of the growth and angiogenesis in and endothelial cells the by and of and endothelial by in and the by the is by and study that the of in the of that growth of endometriotic lesions. a an of that endometriotic growth and of the of endothelial and of endothelial growth by the angiogenesis of by and endothelial and growth and endothelial growth In data suggest that by cells is by the of the of from the is a role in bone is that in the endometriotic in a progenitor that is in endometriotic and growth of in a of the this the in the In angiogenesis in a and in the of the is that the of the is that bone marrow–derived endothelial cells in a of the of angiogenesis in the establishment and growth of endometriotic and the that endothelial progenitor cells in the of the is the a and in the disease and the of endothelial progenitor and endothelial cells in and and of of disease debilitating and of and In is is of the of the endometriotic the and of a a and of of in of in and and of a of of the of of of endometriotic of the In the is the and is and of an the and In an of and a of Endometriosis and the the of the the of by and that the of a is the establishment and growth of endometriotic and in in of angiogenesis a of and in the growth of endometriotic of in a of of endothelial growth growth and growth of angiogenesis and in endometriotic a of of endothelial of in disease and of in and of endothelial cells endothelial cells from the bone of progenitor endothelial cells endothelial endothelial growth is in endometriotic and of endothelial growth in endothelial growth in of of endothelial growth in the angiogenesis the and in the of is a the of bone marrow–derived endothelial progenitor cells by bone endothelial progenitor in by of and and in by of endothelial growth in of the of of in and the of of the progenitor cells the in progenitor cells of and of endothelial and cells angiogenesis and endothelial and of and the of endothelial cells from of endothelial growth endothelial and endothelial a of that and disease and of in of the of Endometriosis and growth angiogenesis of in the of an of growth and in this study the role of of an of of and a bone the of the of endometriotic lesions. the of and and in the and in and and by the and of from from and from a from of cells of and bone in of and a of from of the of the by the growth of endometriotic the the in and Endometriosis the growth of endometriotic endothelial in and in a of in a the of in the the a and in a in of a and the the the endometrial the a a in the that of endometrial tissue. in the of the and the the of the of a the of a the growth of endometriotic and growth of in a of of the of the a In of the in a and of the an of the angiogenesis by and in and the of the the of In the bone bone endometriotic from progenitor cells In bone from and and bone bone the of the in bone by of and in the of of the of of by and of and of endothelial cells of endothelial growth endothelial and endothelial a of and the and of endothelial progenitor the endothelial growth of endothelial progenitor cells the the of cells in and endometriotic from that a bone and in the in and in and and in and the the a and data and and in endothelial angiogenesis by a and of endothelial growth endothelial and endothelial a of endothelial cells in and and bone marrow–derived progenitor endothelial cells of endothelial growth endothelial and endothelial a of and the and of endothelial progenitor the endothelial growth of endothelial progenitor endothelial in and and an in and in and and the and from in in and in that a and progenitor cells of and in of cells of and and the and data and data in of of the of of in the and in and and by the and of from from and from a from of cells of and bone in of and a in the and in and and by the and of from from and from a from of cells of and bone in of and a of from of the of the by the growth of endometriotic the the in and Endometriosis the growth of endometriotic endothelial in and in a of in a the of in the the a and in a in of a and the the the endometrial the a a in the that of endometrial tissue. in the of the and the the of the of a the of a the growth of endometriotic and growth of in a of of the of the a In of the in a from of the of the by the growth of endometriotic the the in and Endometriosis the growth of endometriotic endothelial in and in a of in a the of in the the a and in a in of a and the the the endometrial the a a in the that of endometrial tissue. in the of the and the the of the of a the of a the growth of endometriotic and growth of in a of of the of the a In of the in a and of the an of the angiogenesis by and in and the of the the of In the bone bone endometriotic from and of the an of the angiogenesis by and in and the of the the of In the bone bone endometriotic from progenitor cells In bone from and and bone bone the of the in bone by progenitor cells In bone from and and bone bone the of the in bone by of and in the of of the of of by and of and of endothelial cells of endothelial growth endothelial and endothelial a of and the and of endothelial progenitor the endothelial growth of endothelial progenitor cells the the of cells in and endometriotic from that a bone and in the in and in and and in and the the a and data and and in endothelial angiogenesis by a and of endothelial growth endothelial and endothelial a of endothelial cells in and and bone marrow–derived progenitor endothelial cells of endothelial growth endothelial and endothelial a of and the and of endothelial progenitor the endothelial growth of endothelial progenitor endothelial in and and in the of of the of of by and of and of endothelial cells of endothelial growth endothelial and endothelial a of and the and of endothelial progenitor the endothelial growth of endothelial progenitor cells the the of cells in and endometriotic from that a bone and in the in and in and and in and the the a and data and and in endothelial angiogenesis by a and of endothelial growth endothelial and endothelial a of endothelial cells in and and bone marrow–derived progenitor endothelial cells of endothelial growth endothelial and endothelial a of and the and of endothelial progenitor the endothelial growth of endothelial progenitor endothelial in and and an in and in and and the and from in in and in that a and and an in and in and and the and from in in and in that a and progenitor cells of and in of cells of and and the and data and data in of of the of of progenitor cells of and in of cells of and and the and data and data in of of the of of in a of the of in a of by in endometriotic lesions. of endothelial growth endothelial and endothelial a of by of endothelial and and the of and by and in a of and of of endothelial growth endothelial and endothelial a of progenitor cells In the of and a the the the and of the of of angiogenesis in of the of angiogenesis in a in the that a and the of the of endometriotic disease a in a in the and a from the in of and in the and in that that a in the by the of bone cells in the in the endometriotic and in the and endometriotic and and endothelial cells by the of and and of a a in the of endothelial cells the endometriotic in cells in endometriotic lesions. bone from endometriotic from and from and and and of and endothelial cells of cells of cells of cells of and endothelial of endometriotic in bone and of and cells of bone marrow–derived cells in endometriotic in bone marrow–derived cells endothelial cells that and of cells in the endometriotic the the of a in the of endothelial cells in endometriotic and in of cells the of endometriotic by an an endothelial that the of endothelial progenitor cells endometriotic the of and endometriotic growth in and growth of in a of of the of is an of of the angiogenesis and of endometriotic by the the of of and of in the and of and of the of an of the angiogenesis the of the of and of and a the of an of of of of the in the the that the of endothelial cells and endothelial progenitor cells in the of an angiogenesis-dependent the of a in the in a of the of in a of by in endometriotic lesions. of endothelial growth endothelial and endothelial a of by of endothelial and and the of and by and in a of and of of endothelial growth endothelial and endothelial a of progenitor cells In the of and a the the the and of the of of angiogenesis in of the of angiogenesis in a in the that a the of in a of by in endometriotic lesions. of endothelial growth endothelial and endothelial a of by of endothelial and and the of and by and in a of and of of endothelial growth endothelial and endothelial a of progenitor cells In the of and a the the the and of the of of angiogenesis in of the of angiogenesis in a in the that a and the of the of endometriotic disease a in a in the and a from the in of and in the and in that that a in the by the of the of endometriotic disease a in a in the and a from the in of and in the and in that that a in the by the of bone cells in the in the endometriotic and in the and endometriotic and and endothelial cells by the of and and of a a in the of endothelial cells the endometriotic in of bone marrow–derived cells in endometriotic in bone marrow–derived cells endothelial cells that and of cells in the endometriotic the the of a in the of endothelial cells in endometriotic and in of cells the of endometriotic by an an endothelial that the of endothelial progenitor cells endometriotic lesions. bone cells in the in the endometriotic and in the and endometriotic and and endothelial cells by the of and and of a a in the of endothelial cells the endometriotic in of bone marrow–derived cells in endometriotic in bone marrow–derived cells endothelial cells that and of cells in the endometriotic the the of a in the of endothelial cells in endometriotic and in of cells the of endometriotic by an an endothelial that the of endothelial progenitor cells endometriotic lesions. the of and endometriotic growth in and growth of in a of of the of is an of of the angiogenesis and of endometriotic by the the of of and of in the and of the in the the that the of endothelial cells and endothelial progenitor cells in the of an angiogenesis-dependent the of a in the endometriotic growth in and growth of in a of of the of is an of of the angiogenesis and of endometriotic by the the of of and of in the and of the in the the that the of endothelial cells and endothelial progenitor cells in the of an angiogenesis-dependent the of a in the the study that endothelial progenitor cells in an of and that cells the of the endometriotic lesions. growth of the of the angiogenesis in a of this of and of a role in the angiogenesis-dependent growth of endometriotic and the of a of disease and of is in that growth disease establishment and the angiogenesis in of endothelial and and of in disease and and of angiogenesis in In the the of bone marrow–derived endothelial progenitor cells the of and the in a that the of the the role of in the and of of endothelial and cells angiogenesis and endothelial in and In that of endothelial cells in the bone marrow–derived of bone marrow–derived cells in the this the of bone marrow–derived endothelial cells a of in the in the of endothelial progenitor and the endothelial progenitor cells and in this in in a that cells of endometriotic in a endothelial cells the the and the that the of the endothelial cells in the data suggest that bone marrow–derived endothelial cells this of is a disease that of in the growth and in endometriotic of of endothelial growth in the angiogenesis the and in the of of growth in from in of is a endothelial cells and of It that plays a role in the of bone progenitor cells by bone endothelial progenitor that is of the the of in this data that in the the and in and by a the by a the In a in of and in the and growth of in a of of in the of and of the of of endometriotic in a in in the that a is in growth and growth by cells from of and progenitor cells from the bone of endothelial progenitor in the of and of in ectopic and of and of and of growth in the of endothelial cells in that a and in this in the that of the and in the of cells from the in that this in the this the in a that of the endothelial cells from the a role a in and in and the by angiogenesis a the of angiogenesis in and of angiogenesis in is an of of the by the angiogenesis and in and that the angiogenesis and the and of endometriotic growth the growth of endometriotic endothelial in and in a a is a angiogenesis that endometriotic of that angiogenesis and the of in the that in and study of and of an angiogenesis in in is an of the growth and angiogenesis in and endothelial cells the by and of and endothelial by in and the by the is by and study that the of in the of that growth of endometriotic lesions. a an of that endometriotic growth and of the of endothelial and of endothelial growth by the angiogenesis of by and endothelial and growth and endothelial growth In data suggest that by cells is by the of the of from the is a role in bone is that in the endometriotic in a progenitor that is in endometriotic and growth of in a of the this the in the In angiogenesis in a and in the of the is that the of the is that bone marrow–derived endothelial cells in a of the of angiogenesis in the establishment and growth of endometriotic and the that endothelial progenitor cells in the of the is the a and in the disease and the of endothelial progenitor and endothelial cells in and and In the study that endothelial progenitor cells in an of and that cells the of the endometriotic lesions. growth of the of the angiogenesis in a of this of and of a role in the angiogenesis-dependent growth of endometriotic and the of a of disease and of Endometriosis is in that growth disease establishment and the angiogenesis in of endothelial and and of in disease and and of angiogenesis in In the the of bone marrow–derived endothelial progenitor cells the of and the in a that the of the lesions. the role of in the and of of endothelial and cells angiogenesis and endothelial in and In that of endothelial cells in the bone marrow–derived of bone marrow–derived cells in the this the of bone marrow–derived endothelial cells a of in the in the of endothelial progenitor and the endothelial progenitor cells and in this in in a that cells of endometriotic in a endothelial cells the the and the that the of the endothelial cells in the data suggest that bone marrow–derived endothelial cells this of Endometriosis is a disease that of in the growth and in endometriotic of of endothelial growth in the angiogenesis the and in the of of growth in from in of is a endothelial cells and of It that plays a role in the of bone progenitor cells by bone endothelial progenitor that is of the the of in this data that in the the and in and by a the by a the In a in of and in the and growth of in a of of in the of and of the of of endometriotic in a in in the that a is in growth and growth by cells from of and progenitor cells from the bone of endothelial progenitor in the of and of in ectopic and of and of and of growth in the of endothelial cells in that a and in this in the that of the and in the of cells from the in that this in the this the in a that of the endothelial cells from the a role a in and in and the by angiogenesis a the of angiogenesis in and of angiogenesis in is an of of the by the angiogenesis and in and that the angiogenesis and the and of endometriotic growth the growth of endometriotic endothelial in and in a a is a angiogenesis that endometriotic of that angiogenesis and the of in the that in and study of and of an angiogenesis in in is an of the growth and angiogenesis in and endothelial cells the by and of and endothelial by in and the by the is by and In study that the of in the of that growth of endometriotic lesions. a an of that endometriotic growth and of the of endothelial and of endothelial growth by the angiogenesis of by and endothelial and growth and endothelial growth In data suggest that by cells is by the of the of from the is a role in bone is that in the endometriotic in a progenitor that is in endometriotic and growth of in a of the this the in the In angiogenesis in a and in the of the is that the of the is In that bone marrow–derived endothelial cells in a of the of angiogenesis in the establishment and growth of endometriotic and the that endothelial progenitor cells in the of the is the a and in the disease and the of endothelial progenitor and endothelial cells in and and and the of the and and data and of and and from and the endothelial cells characterized and progenitor and and of and and from and the endothelial cells characterized and progenitor and in of a of cells that the from and and of and and
Full text 31,157 characters · extracted from pmc-nxml · 3 sections · click to expand

Results

To examine the levels of EPCs in a mouse model of endometriosis, we initially measured EPC counts by flow cytometry in C57BL/6 mice with four syngeneic endometriotic lesions. As we have previously described, 30 EPCs were identified by their expression of three cell surface markers including CD31 (endothelial marker), Flk-1 (VEGFR-2, endothelial marker), and CD133 (Prominin-1, stem cell marker) and the absence of CD45 (hematopoietic cell marker) (see Supplemental Figure S1 at http://ajp.amjpathol.org ). To distinguish between CECs and EPCs, further characterization was done by gating on CD133 and CD31 expression. Similar to previous reports, in a typical experiment with C57BL/6 mice we found 0.2 to 0.5 EPC per microliter of blood and five to 10 CECs per microliter of blood. 30 , 40 In the presence of four and six lesions, a highly statistically significant overall difference between the three groups was observed 1 week after endometriosis surgery (four lesions: F = 51.48, P < 0.0001, Figure 1 A; six lesions: F = 8.41, P = 0.001, Figure 1 B). However, the difference between the endometriosis and sham groups were only marginally significant or not significant. Because various inbred murine genetic backgrounds have been demonstrated to have variable angiogenic responses, 31 , 46 we chose to examine one of the most angiogenic strains, 129/SvJ mice. Thus we implanted six lesions per mouse into 129/SvJ mice, which have been shown to have baseline higher circulating EPC levels. 46 Our studies demonstrated a significant overall mean difference between groups ( Figure 1 C) (F = 7.39, P = 0.003). Statistical analysis further indicated significantly higher circulating blood EPC levels in the endometriosis group compared with control subjects ( P = 0.007) or compared with mice that underwent a sham operation ( P = 0.007) ( Figure 1 C). No significant difference was detected between sham treated mice versus control subjects ( P = 0.99). To determine whether the numbers of EPCs or CECs fluctuated over time after the implantation of endometriotic lesions, mice were terminally bled on various days after disease initiation. We found a highly significant change in lesion area over time (F = 15.78, P < 0.001), with posthoc analysis revealing a significant reduction in the first 10 days ( P = 0.04) and then a dramatic increase from day 10 to day 28 ( P < 0.001). We next examined the changes in mean EPCs per microliter of whole blood between sham and endometriosis groups at specific time points. Our results indicated overall significantly greater circulating EPC levels in the endometriosis group (F = 10.54, P = 0.002) ( Figure 2 B) with significant differences at 1 day ( P = 0.008), 4 days ( P = 0.03), and 10 days ( P = 0.04) but no differences at 7 days ( P = 0.48), 14 days ( P = 0.30), or 28 days ( P = 0.47). Figure 2 Blood levels of endothelial cells over time. Whole blood was collected from mice with six endometriotic lesions after different time points ( n = 5 per time point and group). A: Following blood collection, endometriotic lesions were measured with a caliper using the formula of an ellipse as previously described. 12 , 34 , 37 , 38 , 77 Values shown are mean ± SEM. B: EPCs stained negative for CD45 and positive for CD31, VEGRR-2, and CD133 (* P ≤ 0.04; ** P = 0.008; posthoc Bonferroni test). C: CECs stained negative for CD45 and CD133 and positive for CD31 and VEGFR-2 [endometriosis group (black squares); sham operated group (white diamonds)] (** P < 0.001; posthoc Bonferroni test). Blood levels of endothelial cells over time. Whole blood was collected from mice with six endometriotic lesions after different time points ( n = 5 per time point and group). A: Following blood collection, endometriotic lesions were measured with a caliper using the formula of an ellipse as previously described. 12 , 34 , 37 , 38 , 77 Values shown are mean ± SEM. B: EPCs stained negative for CD45 and positive for CD31, VEGRR-2, and CD133 (* P ≤ 0.04; ** P = 0.008; posthoc Bonferroni test). C: CECs stained negative for CD45 and CD133 and positive for CD31 and VEGFR-2 [endometriosis group (black squares); sham operated group (white diamonds)] (** P < 0.001; posthoc Bonferroni test). We then investigated CEC levels in mice that had endometriosis versus mice that underwent a sham operation over time. Overall, significantly higher CEC levels were found in the endometriosis group (F = 4.21, P = 0.04) ( Figure 2 C), which was confirmed by posthoc analysis for day 1 ( P < 0.001), but not thereafter. Endometriotic lesions were implanted into irradiated wild-type mice transplanted with GFP-expressing bone marrow. Endothelial cells in the circulation, in the endometriotic lesions, and in the uterine tissue were quantified at various time points after surgery. Uterine tissue and endometriotic lesions were isolated and dissociated into single cell suspensions, and endothelial cells were identified using flow cytometry by the expression of two different cell surface markers (CD31 + and VEGFR2 + ) and exclusion of a hematopoietic cell surface antigen (CD45 − ) ( Figure 3 A). We detected a highly significant increase over time in the numbers of endothelial cells incorporated into the endometriotic lesions at 21 days (F = 31.97, P < 0.001) but no change in uterine tissue (F = 1.73, P = 0.21). Figure 3 Endothelial cells in endometriotic lesions. After irradiating with lethal doses, mice received GFP +/+ bone marrow from donor mice. Six weeks later, endometriotic lesions from wild-type animals were implanted into these mice. Lesions and uterine tissue were removed at different time points from different mice ( n = 5 per group and time point), digested, and single cell suspensions were stained and measured using flow cytometry [endometriotic lesions (black squares); uterine tissue (white diamonds)]. A: Percentage of CD45 − , CD31 + , and VEGFR-2 + endothelial cells of all cells were measured. B: Percentage of GFP + cells of all cells measured. C: Percentage of CD45 − , CD31 + , VEGFR-2 + , and GFP + endothelial cells. Values shown are mean ± SEM (* P < 0.003; ** P < 0.001; posthoc Bonferroni test). D: Immunohistochemistry of wild-type endometriotic lesions in irradiated mice with transplanted GFP + bone marrow. GFP fluorescence ( middle panel ) and after staining for CD31 (Cy-3; left panel ). Fluorescent confocal microscopy showed some co-localization of GFP + and CD31 + cells ( right panel ; bar = 50 μmol/L). Endothelial cells in endometriotic lesions. After irradiating with lethal doses, mice received GFP +/+ bone marrow from donor mice. Six weeks later, endometriotic lesions from wild-type animals were implanted into these mice. Lesions and uterine tissue were removed at different time points from different mice ( n = 5 per group and time point), digested, and single cell suspensions were stained and measured using flow cytometry [endometriotic lesions (black squares); uterine tissue (white diamonds)]. A: Percentage of CD45 − , CD31 + , and VEGFR-2 + endothelial cells of all cells were measured. B: Percentage of GFP + cells of all cells measured. C: Percentage of CD45 − , CD31 + , VEGFR-2 + , and GFP + endothelial cells. Values shown are mean ± SEM (* P < 0.003; ** P < 0.001; posthoc Bonferroni test). D: Immunohistochemistry of wild-type endometriotic lesions in irradiated mice with transplanted GFP + bone marrow. GFP fluorescence ( middle panel ) and after staining for CD31 (Cy-3; left panel ). Fluorescent confocal microscopy showed some co-localization of GFP + and CD31 + cells ( right panel ; bar = 50 μmol/L). The percentage of GFP-positive bone marrow–derived cells was significantly elevated in endometriotic lesions after 21 days (F = 30.62, P < 0.001) but remained constant in uterine tissue (F = 0.88, P = 0.48) ( Figure 3 B). To determine whether GFP bone marrow–derived cells were endothelial cells, we analyzed GFP + cells that were also VEGFR2 and CD31 positive but negative for CD45 ( Figure 3 C). None of these cells could be detected in the endometriotic lesions on the day after the transplantation. Two-way analysis of variance confirmed a highly significant increase over time in the percentage of GFP-positive endothelial cells in endometriotic tissue (F = 33.06, P < 0.001) and in uterine tissue (F = 21.69, P = 0.003). Furthermore, incorporation of GFP-positive cells into the vasculature of endometriotic lesions was confirmed by immunofluorescence with an antibody to CD31, an endothelial cell specific marker that co-localized with GFP expression ( Figure 3 D). These studies confirmed the presence of endothelial progenitor cells incorporated into endometriotic lesions. Anti-angiogenic therapy has been shown to suppress endometriotic growth in various mouse models. 15 , 37 , 38 Lodamin is an oral nontoxic formulation of TNP-470, one of the most potent angiogenesis inhibitors known to date. 39 Cohorts of wild-type mice were either designated as control (untouched) or had sham surgery or endometriotic lesions implanted. Mice were then treated daily with either 15 mg/kg Lodamin or vehicle alone by oral gavage. Weight loss among the different cohorts was not statistically significant, indicating the lack of toxicity with daily Lodamin treatment for 1 week (data not shown). After 1 week of treatment, blood was drawn to measure both CEC and EPC concentrations. Statistical analysis indicated significantly lower CECs per microliter of whole blood for treatment compared with vehicle in the endometriosis group ( P = 0.02) but no significant difference between vehicle and treatment for control ( P = 0.09) or sham ( P = 0.21) groups ( Figure 4 A). Figure 4 Effect of antiangiogenic treatment on EPCs and CECs. Female 129 SvJ mice underwent endometriosis or sham surgery or no surgery (control subjects) ( n = 10 per group). Half of the mice of each group received 15 mg/kg Lodamin (Tx; black columns ), an oral, nontoxic form of the angiogenesis inhibitor TNP-470, over 7 days. Control subjects received vehicle (V; white columns ). Whole blood was taken at the end of the experiment, stained for ( A ) CEC markers (CD45 − , CD31 + , VEGFR-2 + , CD133 − ) (* P = 0.02; two-way analysis of variance) and ( B ) EPC markers (CD45 − , CD31 + , VEGFR-2 + , CD133 + ) (** P < 0.001; two-way analysis of variance) and measured using flow cytometry. C: Endometriosis-like lesions were measured with a caliper using the formula of an ellipse. Mean cross-sectional area of endometriosis-like lesions ( n = 6 lesions) of mice treated with vehicle or Lodamin (* P = 0.022; repeated-measures analysis of variance). Values shown are mean ± SEM. Effect of antiangiogenic treatment on EPCs and CECs. Female 129 SvJ mice underwent endometriosis or sham surgery or no surgery (control subjects) ( n = 10 per group). Half of the mice of each group received 15 mg/kg Lodamin (Tx; black columns ), an oral, nontoxic form of the angiogenesis inhibitor TNP-470, over 7 days. Control subjects received vehicle (V; white columns ). Whole blood was taken at the end of the experiment, stained for ( A ) CEC markers (CD45 − , CD31 + , VEGFR-2 + , CD133 − ) (* P = 0.02; two-way analysis of variance) and ( B ) EPC markers (CD45 − , CD31 + , VEGFR-2 + , CD133 + ) (** P < 0.001; two-way analysis of variance) and measured using flow cytometry. C: Endometriosis-like lesions were measured with a caliper using the formula of an ellipse. Mean cross-sectional area of endometriosis-like lesions ( n = 6 lesions) of mice treated with vehicle or Lodamin (* P = 0.022; repeated-measures analysis of variance). Values shown are mean ± SEM. When we looked at EPCs, overall highly significant differences were observed (F = 6.72, P = 0.006), with significantly lower EPCs per microliter after treatment of the endometriosis ( P < 0.001), but no significant differences in the control group ( P = 0.11) or the sham group ( P = 0.07) ( Figure 4 B). This finding could indicate that anti-angiogenic therapy with Lodamin suppresses the mobilization of both circulating endothelial cells and endothelial progenitor cells in the presence of an angiogenesis-dependent disease. When the lesion size was measured after 1 week of Lodamin treatment, results indicated a significantly smaller lesion area in the Lodamin group compared with vehicle (1.74 mm 2 versus 1.41 mm 2 , F = 7.99, P = 0.022) ( Figure 4 C).

Material

All procedures were performed in the animal facility at Children's Hospital, Boston, MA. All animal handling and procedures were performed in accordance with federal, local, and institutional guidelines and were approved by the Institutional Animal Care and Use Committee of Children's Hospital. Eight-week-old female 129 × 1/SvJ mice were purchased from Jackson Laboratories (Bar Harbor, MN); 129S6/SvEvTac mice were purchased from Taconic Farms (Hudson, NY), and C57BL/6 mice were purchased from Charles River Laboratories (Wilmington, MA). C57BL/6J-GFP-mice were a generous gift from Dr. Taturo Udagawa. 32 The mice were caged in groups of five to 10 with free access to chow and water; they were acclimated for 3 weeks before any experiment. The animal room was kept constantly at 26°C, 38.5% humidity, with a 12-hour light, 12-hour dark cycle (7:30 AM to 7:30 PM). Mice received no hormonal treatment. Mice were randomly taken from different cages to minimize any potential effects of the stage of the estrous cycle, which was determined by vaginal smears as previously described. 12 Consequently, the stages were evenly distributed across the different groups in all experiments (data not shown). All surgical procedures were performed under inhalational anesthesia with isoflurane (Baxter, Deerfield, IL), and mice were observed until they fully recovered. Endometriosis was surgically induced as described previously. 33 , 34 , 35 , 36 Briefly, the uterine horns were removed through a midline abdominal incision and opened longitudinally in a Petri dish containing warmed 0.9% saline solution. Four or six biopsy specimens (2 mm in diameter) were obtained with use of a dermal biopsy punch (Miltex, Bethpage, NY), and the lesions were autotransplanted to the peritoneal wall with the endometrial side facing the peritoneum using a braided 7–0 silk suture (Ethicon, Somerville, NJ). The wound was closed with a 5–0 suture (Ethicon). Identical procedures were performed in the “sham group” except that sutures alone were inserted instead of endometrial tissue. Mice in the “control group” did not undergo surgery. For initial experiments ( Figure 1 ), blood was taken 1 week after inoculation with endometriosis. For all of the other experiments, blood was drawn and mice were sacrificed at the indicated time points. At the end of the experiment, lesions were measured at their implantation site as described previously: two perpendicular diameters (D 1 , D 2 ) of each lesion were measured with a caliper to the nearest tenth of a millimeter. 12 , 37 , 38 Lesion volumes were determined using the formula for a sphere (volume = D 1 × D 2 × π/4). Lesions were then excised for further processing. In some groups of mice the uteri also were removed for further analysis (described in a later section). Figure 1 Blood EPC numbers in mice. Female mice received endometriotic (black columns) or sham lesions (gray columns) during abdominal surgery or were not operated upon (control subjects, white columns). Whole blood was taken after 1 week and stained for EPC markers (flow cytometry). Female C57BL/6 mice received four lesions ( A ) or six lesions ( B ) (* P < 0.05; ** P < 0.001, posthoc Bonferroni test). Female 129SvJ mice received six lesions ( C ). All experiments were performed with n = 10 per group. Values shown are mean ± SEM (* P < 0.05; ** P = 0.007, posthoc Bonferroni test). Blood EPC numbers in mice. Female mice received endometriotic (black columns) or sham lesions (gray columns) during abdominal surgery or were not operated upon (control subjects, white columns). Whole blood was taken after 1 week and stained for EPC markers (flow cytometry). Female C57BL/6 mice received four lesions ( A ) or six lesions ( B ) (* P < 0.05; ** P < 0.001, posthoc Bonferroni test). Female 129SvJ mice received six lesions ( C ). All experiments were performed with n = 10 per group. Values shown are mean ± SEM (* P < 0.05; ** P = 0.007, posthoc Bonferroni test). 129S6/SvEvTac mice were divided into three groups (“endometriosis,” “sham,” and “control”; n = 20/group). Half of the mice received 15 mg/kg Lodamin, an oral formulation of the angiogenesis inhibitor TNP-470, or vehicle daily by oral gavage for 14 days. 39 Mice were monitored daily for changes in weight. Daily vaginal smears were taken, and uterine horns were removed at the end of the experiment to determine the potential effect of Lodamin on estrous cycling. In the bone marrow transplantation experiments, C57BL/6J mice with transplanted green fluorescent protein (GFP) bone marrow received endometriotic tissue from wild-type C57BL/6J mice. Bone marrow transplantation was performed as described previously. 40 In brief, bone marrow was harvested from C57BL/6J-GFP mice. The donor mice were euthanized using carbon dioxide, and their femurs were dissected and then flushed with 1 mL sterile 0.9% saline solution to collect bone marrow. Anesthetized recipient C57BL/6 mice (Charles River Laboratories) were lethally irradiated with 950 Gy. The harvested GFP bone marrow was then injected into the retro-orbital plexus of into the irradiated recipients in 100 μL 0.9% saline solution. The bone marrow was allowed to engraft for 6 weeks. Engraftment was verified by GFP-positive blood samples before endometriosis induction. Circulating EPCs and CECs were measured in the peripheral blood of all of the mice. After induction of anesthesia using isoflurane, 500 μL to 1000 μL of blood was collected by retro-orbital puncture and anticoagulated with use of sodium citrate. Blood was kept on ice until processing, and 150 μL of blood was used to quantify circulating endothelial cells using four-color flow cytometry as previously described. 30 , 41 , 42 Red blood cells were lysed using FACSLyse Solution (BD Biosciences, San Jose, CA), according to the manufacturer's directions. For the fluorescence-activated cell sorting analysis of GFP-positive cells in tissue, eutopic endometrium and endometriotic lesions were taken from mice that had undergone a bone marrow transplantation and wild-type mice. Tissue was incubated in Dispase 2 (Roche, Nutley, NJ) for 30 minutes at 37°C per the manufacturer's instructions to dissociate tissue into single-cell suspensions, re-suspended in Dulbecco's modified Eagle's medium with 10% fetal bovine serum to neutralize enzymes, and washed in PBS with 1% bovine serum albumin before staining with antibodies and performing fluorescence-activated cell sorting analysis. The following directly conjugated antibodies were used to detect EPCs and CECs in peripheral mouse blood: anti-mouse CD45-PerCP, CD31-APC (platelet/endothelial cell adhesion molecule-1), Flk-1-PE (mouse VEGFR-2; all BD Biosciences, San Jose, CA), and CD133-fluorescein isothiocyanate (Prominin-1; eBioscience, San Diego, CA). Tissue was stained with the same antibodies except the CD133 fluorescein isothiocyanate antibody. Flow cytometry was performed using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA) and acquired data were analyzed with FLOWJO flow cytometry analysis software (Treestar, Ashland, OR), with analysis gates designed to remove residual platelets and cellular debris. Fluorescence minus one control subjects were used for gating. Between 500,000 and 1000,000 events were counted in each sample. SV40-transformed murine endothelial (MS-1) cells 43 were spiked into blood samples as a positive control for compensation and gating purposes. 30 Circulating endothelial cells in mouse peripheral blood were assessed using flow cytometry and then classified into mature (CECs: CD45 − , VEGFR-2 + , CD31 + , CD133 − ) and bone marrow–derived progenitor endothelial cells (EPCs: CD45 − , VEGFR-2 + , CD31 + , CD133 + ) as previously described. 30 , 41 , 42 , 44 Immunohistochemical staining was carried out on 8-μm frozen sections. For CD31-Cy3 staining, sections were dried for 2 to 3 hours at room temperature and circled with an Immedge Pen (Vector Laboratories, Burlingame, CA). Sections were immersed in 0.3% Triton X-100 PBS (T-PBS), washed twice with PBS, and then blocked for 1 hour with 5% goat serum (Jackson ImmunoResearch, West Grove, PA) in PBS + 0.3% Triton X-100 + 0.01% bovine serum albumin + 0.01% Thimerosal. The same solution without goat serum was used to dilute antibodies. Incubation with primary antibody (rat anti-mouse CD31, 1:500, BD Biosciences) was carried out overnight. Slides were then washed with T-PBS and incubated with secondary antibody (Cy3-goat anti-rat 1:400, Jackson ImmunoResearch) for 4 to 5 hours. Slides were then washed with T-PBS and fixed with 4% paraformaldehyde for 15 minutes. The final washes with PBS were done before mounting with Vectashield Mounting Medium with DAPI (Vector Laboratories) according to the manufacturer's instructions. Uterine horns and ovaries were removed from mice in all groups after Lodamin treatment. Tissues were snap frozen in liquid nitrogen and mounted in OCT embedding medium (Thermo Fisher Scientific, Waltham, MA). Sections that were 5- to 7-μm thick were cut on a cryostat machine and stained with H&E. All statistical comparisons were done using SigmaStat software (Aspire Software International, Leesburg, VA) as previously described. 40 The number of mature CECs and EPCs detected in each mouse was expressed as absolute number of cells per microliter of blood analyzed. Mean CEC and EPC values were then calculated and compared between the different groups. Means and Student's t -test for parametric data or median and rank-sum test for nonparametric data were applied to compare groups. EPCs in whole blood were compared using one-way analysis of variance (analysis of variance) with posthoc testing based on the Bonferroni procedure to minimize type I errors (false-positive results) due to multiple group comparisons. 45 Lesion size was compared with use of repeated-measures analysis of variance.

Discussion

In the present study we show that circulating endothelial progenitor cells are elevated in an established mouse model of endometriosis and provide evidence that these cells incorporate into the growing vasculature of the endometriotic lesions. EPC up-regulation appears to be highest during early lesion establishment, coinciding with increased vascular growth as previously demonstrated. 38 However, treatment with the potent angiogenesis inhibitor Lodamin resulted in a significant inhibition of this surge of circulating EPCs and subsequent suppression of lesion growth. These findings imply a potential role for EPCs in the angiogenesis-dependent growth of endometriotic lesions and may indicate the use of EPCs as a biomarker of disease progression and surrogate marker of treatment efficacy. Endometriosis is similar to tumors in that it requires blood vessel growth for disease establishment and progression. Although the exact mechanisms are unknown, angiogenesis has been proposed to occur in endometriosis through classic mechanisms such as proliferation of endothelial and supporting cells, intussusception, and elongation of existing blood vessels. 16 , 47 In our current study, we demonstrate for the first time another possible mechanism, the incorporation of bone marrow–derived circulating endothelial progenitor cells into the growing vascular tree. Blood EPC levels rose within 2 days of “disease” induction and peaked during the first 10 days, in a manner that was inversely correlated with the size of the lesions. Considerable debate exists about the role of EPCs, in particular regarding the extent and significance of their incorporation into tumor vasculature. 28 , 44 In our study, we found that up to 37% of all endothelial cells in the lesions were bone marrow–derived 1 week after transplantation. No significant increase of general bone marrow–derived cells in the uterus was observed during this period. However, the percentage of bone marrow–derived endothelial cells did increase over time, which may be a result of changes in the estrous cycle in these animals. Human studies have shown higher blood EPC levels during the follicular 48 and the luteal phase, 49 but in this model, we did not see estrous cycle–related differences in blood EPC levels (data not shown). Eggermont et al demonstrated in a xenotransplant model that human lesions contained murine CD31-positive cells as early as day 5 after implantation, peaking around day 15. 50 Because host endothelial cells invaded the interface between the peritoneal stroma and the lesion, they suggested that the source of the endothelial cells most likely was in the proliferating surrounding blood vessels. Our data suggest that bone marrow–derived endothelial cells may contribute to this process of blood vessel growth, especially during early lesion establishment. Endometriosis is a chronic, progressive disease that frequently presents with multiple sites of extra-uterine tissue in the peritoneal cavity. Pro-angiogenic factors such as VEGF, basic fibroblast growth factor, and IL-8 are elevated in endometriotic tissue, peritoneal fluid, or serum of patients with endometriosis. 21 , 51 , 52 VEGF is a well-studied mitogen for endothelial cells and strongly increases vascular permeability. 53 It has been previously demonstrated that VEGF plays a significant role in the mobilization of bone marrow– derived progenitor cells for postnatal neovascularization. 22 Assuming that VEGF is one of the main stimuli for the recruitment of EPCs in this model, our current data support our previous findings that showed high VEGF levels in the transplanted lesions during the first week after transplantation. This rise and subsequent fall in EPC concentration and VEGF expression could be explained by a hypoxic environment after the lesions lose their blood supply followed by a normoxic one once the lesions acquire new blood vessels. In fact, we have previously demonstrated a concomitant rise in levels of hypoxia inducible factor-1 α and its downstream target, VEGF, in these lesions during the first few days after transplantation. 37 Concentrations of both molecules decline thereafter when neovascularization results in the delivery of oxygen and nutrients. 38 , 50 The small, delayed rise in blood EPC levels in the mice that underwent a sham operation is possibly due to wound healing in these animals. Other factors have been shown to stimulate EPC recruitments such as stromal cell-derived factor-1, placental growth factor, and matrix metalloprotease-9. 54 , 55 , 56 Interestingly, they all have been associated with endometriosis. 57 , 58 , 59 , 60 Blood levels of mature endothelial cells also rose in both mice that underwent a sham operation and in mice with endometriosis, although this effect was delayed in the sham group. We speculate that wound healing, mainly of the abdominal wall and uterine stump, resulted in the shedding of these cells from the local tissue in all animals. The fact that this phenomenon occurred earlier in the endometriosis group supports this theory, because transplantation increases the tissue burden undergoing regeneration. CEC concentrations in both groups were similar after a few days, suggesting that most of the endothelial cells originating from the transplanted lesions had gone. Anti-angiogenic therapy may have a role as a novel therapeutic approach in patients with endometriosis. 9 However, potential teratogenicity and inhibitory effects on the reproductive system demonstrated by some angiogenesis inhibitors are posing a significant hurdle to the clinical testing of angiogenesis inhibitors in patients with endometriosis. 47 , 61 , 62 , 63 We previously demonstrated that the endogenous angiogenesis inhibitor endostatin and its fragment mP-1 had no negative effects on the reproductive cycle and offspring of mice, while endometriotic growth was suppressed. 12 , 34 TNP-470, a synthetic fumagillin analog, is a very powerful angiogenesis inhibitor that has been shown to inhibit endometriotic growth 15 , 64 , 65 but that caused neurotoxicity in clinical trials. 66 , 67 Lodamin is an oral, nontoxic form of the fumagillin derivative TNP-470, which inhibits tumor growth and angiogenesis in mice. 39 Possible TNP-470 mechanisms on endothelial cells include affecting the cell cycle through p53 activation by binding to methionine aminopeptidase (MetAP-2), preventing Rac1 activation and induction of p21 (CIP/WAF). 68 , 69 , 70 In our current study we found that Lodamin suppressed the levels of EPCs in the blood of mice that had endometriosis while inhibiting growth of endometriotic lesions. We have seen a similar effect with caplostatin (unpublished data), an injectable, nontoxic formulation of TNP-470 that inhibited endometriotic growth and angiogenesis. 38 TNP-470 has been shown to inhibit VEGF-induced endothelial cell growth, migration, and vascular hyperpermeability. 71 , 72 , 73 In vitro data suggest that VEGF expression by tumor cells is inhibited by TNP-470. 74 Because VEGF is considered to play a central role in bone marrow recruitment, it is conceivable that TNP-470 treatment inhibits VEGF expression in the endometriotic lesions, resulting in a reduced stimulus for EPC mobilization. 75 We have previously demonstrated that VEGF is highly up-regulated in endometriotic tissue through hypoxia inducible factor-1 α. 37 Therefore if the TNP-470 derivative Lodamin inhibits this pathway it could explain the effect on EPC levels in the treated animals. In fact, Lodamin inhibits VEGF-induced angiogenesis in a mouse corneal micropocket assay. 39 Treatment with Lodamin resulted in the arrest of the estrous cycle at metestrus (data not shown). Therefore it is conceivable that the potential effect of the drug on estrogen levels also may affect EPC (and CEC levels). This question is currently under investigation. In summary, we demonstrate that bone marrow–derived endothelial cells contribute to neovascularization in a mouse model of endometriosis. These findings highlight the importance of angiogenesis in the establishment and growth of endometriotic lesions, and they also support the hypothesis that endothelial progenitor cells are involved in the pathogenesis of the disease. 76 From a clinical perspective it will be highly interesting to investigate EPC and CEC levels in women who have the disease and the effect of therapy on these levels. If circulating endothelial progenitor and mature endothelial cells are elevated in patients, they may be promising and much needed biomarkers for both diagnosis and therapeutic efficacy.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: pmc-nxml ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Endometriosis Endothelial Cells Stem Cells Administration, Oral Angiogenesis Inhibitors Angiogenesis Inhibitors Animals Bone Marrow Transplantation Cell Separation Cyclohexanes Cyclohexanes Disease Models, Animal Endometriosis Endometriosis Endothelial Cells Female Flow Cytometry Green Fluorescent Proteins Green Fluorescent Proteins Immunohistochemistry

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (84)

Cited by (50)

Source provenance

europepmc
last seen: 2026-07-25T06:15:30.875455+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:16:48.482574+00:00
License: CC0 · commercial use OK